Your session is about to expire
← Back to Search
Photosensitizing Agent
MAL Cream Arm for Actinic Keratosis
Phase 3
Waitlist Available
Research Sponsored by Galderma R&D
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at week 28 and week 54
Awards & highlights
Study Summary
This trial is checking to see if the skin condition Actinic Keratosis comes back after being treated in an earlier study.
Eligible Conditions
- Actinic Keratosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at week 28 and week 54
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at week 28 and week 54
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With Recurrence of Any (>=1) Cleared Treated AK Lesions at Week 54
Secondary outcome measures
Number of Participants With Recurrence of Any (>=1) Cleared Treated AK Lesions at Week 28
Percent Recurrence of Cleared Treated AK Lesions at Week 28 and Week 54
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: MAL Cream ArmActive Control1 Intervention
Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit of the active cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
Group II: Vehicle Cream ArmPlacebo Group1 Intervention
Participants who completed the study RD.06.SPR.112199 (NCT04085367) and achieved complete response of all treated lesions at the final visit in the vehicle cream group, will continue for long-term follow-up to evaluate recurrence of AKs in this study.
Find a Location
Who is running the clinical trial?
Galderma R&DLead Sponsor
300 Previous Clinical Trials
60,352 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger